Von Holzen U - Search Results

1

Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma.

Roh V, Laemmle A, Von Holzen U, Stroka D, Dufour JF, Hunt KK, Candinas D, Vorburger SA. Roh V, et al. Among authors: von holzen u. Cancer Gene Ther. 2008 Oct;15(10):636-44. doi: 10.1038/cgt.2008.34. Epub 2008 Jun 6. Cancer Gene Ther. 2008. PMID: 18535617

2

Role for the double-stranded RNA-activated protein kinase PKR in Ad-TNF-alpha gene therapy in esophageal cancer.

von Holzen U, Bocangel D, Pataer A, Vorburger SA, Liu Y, Lu X, Hunt KK, Swisher SG. von Holzen U, et al. Surgery. 2005 Aug;138(2):261-8. doi: 10.1016/j.surg.2005.04.011. Surgery. 2005. PMID: 16153435

3

The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation.

von Holzen U, Pataer A, Raju U, Bocangel D, Vorburger SA, Liu Y, Lu X, Roth JA, Aggarwal BB, Barber GN, Keyomarsi K, Hunt KK, Swisher SG. von Holzen U, et al. Clin Cancer Res. 2007 Oct 15;13(20):6032-9. doi: 10.1158/1078-0432.CCR-06-2932. Clin Cancer Res. 2007. PMID: 17947465

4

A surprise cell of origin for Barrett's esophagus.

von Holzen U, Enders GH. von Holzen U, et al. Cancer Biol Ther. 2012 Jun;13(8):588-91. doi: 10.4161/cbt.20088. Epub 2012 Jun 1. Cancer Biol Ther. 2012. PMID: 22549156 Free PMC article.

5

Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.

Crawford K, Bontrager E, Schwarz MA, Chaturvedi A, Lee DD, Md Sazzad H, von Holzen U, Zhang C, Schwarz RE, Awasthi N. Crawford K, et al. Among authors: von holzen u. Cancer Biol Ther. 2021 Dec 2;22(10-12):619-629. doi: 10.1080/15384047.2021.2011642. Epub 2021 Dec 9. Cancer Biol Ther. 2021. PMID: 34882068 Free PMC article.

6

Isolated tumor cells in stage I & II colon cancer patients are associated with significantly worse disease-free and overall survival.

Weixler B, Warschkow R, Güller U, Zettl A, von Holzen U, Schmied BM, Zuber M. Weixler B, et al. Among authors: von holzen u. BMC Cancer. 2016 Feb 16;16:106. doi: 10.1186/s12885-016-2130-7. BMC Cancer. 2016. PMID: 26879046 Free PMC article.

7

Animal Model: Xenograft Mouse Models in Esophageal Adenocarcinoma.

Hassan MS, von Holzen U. Hassan MS, et al. Among authors: von holzen u. Methods Mol Biol. 2018;1756:151-164. doi: 10.1007/978-1-4939-7734-5_14. Methods Mol Biol. 2018. PMID: 29600368

8

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.

Hassan MS, Williams F, Awasthi N, Schwarz MA, Schwarz RE, Li J, von Holzen U. Hassan MS, et al. Among authors: von holzen u. Sci Rep. 2019 Nov 26;9(1):17608. doi: 10.1038/s41598-019-54129-7. Sci Rep. 2019. PMID: 31772236 Free PMC article.

9

Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.

Awasthi N, Kronenberger D, Stefaniak A, Hassan MS, von Holzen U, Schwarz MA, Schwarz RE. Awasthi N, et al. Among authors: von holzen u. Cancer Lett. 2019 Sep 10;459:41-49. doi: 10.1016/j.canlet.2019.05.037. Epub 2019 May 30. Cancer Lett. 2019. PMID: 31153980

10

Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.

Grojean M, Schwarz MA, Schwarz JR, Hassan S, von Holzen U, Zhang C, Schwarz RE, Awasthi N. Grojean M, et al. Among authors: von holzen u. J Cell Mol Med. 2021 Jun;25(11):4950-4961. doi: 10.1111/jcmm.16362. Epub 2021 May 3. J Cell Mol Med. 2021. PMID: 33939252 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters